Can a patient with hidradenitis suppurativa develop rheumatoid arthritis? Apparently so, according to researchers writing in JAMA Dermatology this month.
COVID-19 is being treated with treatments designed for rheumatoid arthritis. They have their pros and cons. Learn more in this article.
The American College of Rheumatology recommends treating rheumatoid arthritis early in order to increase the chances of achieving and sustaining remission. Take our clinical quiz to learn more.
Despite the publication of previous clinical trials that showed plasma exchange could possibly be a viable treatment for patients with severe ANCA-associated vasculitis, a new study recently published in the New England Journal of Medicine shows the treatment, in combination with standard therapy, didn't improve outcomes for patients or lower fatality rates or slow the progression to end-stage kidney disease.
The risk of dying from a cardiovascular event can increase by 50 percent for rheumatoid arthritis patients with low serum folate levels, report researchers in JAMA Open Network.
The U.S. Food and Drug Administration has approved the first-ever treatment for chronic fibrosing interstitial lung disease (ILD), a condition that can affect rheumatoid arthritis patients. The treatment is designed for patients with a form of the disease that progressively worsens over time.
Respiratory viral infections can be a novel environmental risk factor for the development of rheumatoid arthritis, find Korean researchers writing in Arthritis Research and Therapy.
What is the connection (if any) between coronavirus and autoimmune diseases? In this slideshow, we feature some points of view from rheumatology experts in the field, including Dr. Jean Liew of the University in Washington, Seattle, who told CreakyJoints that patients with inflammatory arthritis are probably more susceptible to the coronavirus and are at higher risk of complications like pneumonia.
The U.S. Food and Drug Administration has approved a label update for secukinumab (Cosentyx, Novartis) to include the option for up-titration to a 300 mg dose for adults with active ankylosing spondylitis.
Bone mineral density was preserved over a three-year period in patients with rheumatoid arthritis treated with biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDS) but declined in those who received only conventional-synthetic DMARDs, say researchers recently writing in Rheumatology.